Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CSL Behring has received marketing authorization to market Berinert in Israel to treat acute hereditary angioedema (HAE) attacks in any body location.
Subscribe to our email newsletter
According to the company, the Berinert marketing approval is given on the basis of positive results from Phase II/III prospective, double-blind placebo-controlled International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T.1).
CSL Behring already has Berinert marketing rights in the US, Australia, Canada, Germany, Argentina, Japan and Switzerland.
Sheba Medical Center, Israel Allergy & Immunology Unit head Avner Reshef said the approval of Berinert in Israel is a very important step toward optimal treatment of patients with HAE, many of whom have suffered with the symptoms of this debilitating disease for years.